Literature DB >> 23925734

Discriminative-stimulus effects of NS9283, a nicotinic α4β2* positive allosteric modulator, in nicotine-discriminating rats.

Eric G Mohler1, Stanley R Franklin, Lynne E Rueter.   

Abstract

RATIONALE: Neuronal α4β2* nicotinic acetylcholine receptors mediate cognition, pain, and the discriminative and reinforcing effects of nicotine. In addition to traditional orthosteric agonists, α4β2* positive allosteric modulators (PAMs) have recently been identified. With increased subtype selectivity relative to agonists, PAMs administered alone or in combination with low-dose α4β2* agonists may be used as powerful tools for increasing our understanding of α4β2* pharmacology.
OBJECTIVES: The present experiments tested the nicotine discriminative-stimulus effects of the α4β2* PAM NS9283 (A-969933) in the presence and absence of low-dose nicotine or nicotinic subtype-selective agonist.
METHODS: Rats were trained to discriminate 0.4 mg/kg nicotine from saline in a two-lever drug discrimination paradigm. In subsequent generalization tests, rats were administered nicotine, the α4β2*-preferring agonist ABT-594, and NS9283, alone or in two-drug combinations.
RESULTS: Nicotine and ABT-594 showed dose-dependent nicotine generalization. NS9283 alone resulted in a non-significant increase in nicotine-appropriate lever selection. Combination of non-effective doses of nicotine or ABT-594 with escalating doses of NS9283 resulted in a complete conversion to 100 % nicotine-appropriate choice in the case of nicotine combination and incomplete, though significant, generalization for ABT-594.
CONCLUSIONS: The α4β2* PAM NS9283 alone did not produce nicotine-like discriminative effects, but did demonstrate dose-related increases in nicotine lever choice when combined with a non-effective dose of nicotine or the α4β2* agonist ABT-594. This finding provides confirmation of the positive allosteric modulating effect of NS9283 in a functional in vivo paradigm. NS9283 is a potentially valuable tool for studying the role of α4β2* receptors in various nicotinic acetylcholine receptor-related functions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925734     DOI: 10.1007/s00213-013-3207-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

Review 1.  Central nicotinic receptors: structure, function, ligands, and therapeutic potential.

Authors:  M Novella Romanelli; Paola Gratteri; Luca Guandalini; Elisabetta Martini; Claudia Bonaccini; Fulvio Gualtieri
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

2.  Allosteric modulation of nicotinic acetylcholine receptors.

Authors:  Daniel Bertrand; Murali Gopalakrishnan
Journal:  Biochem Pharmacol       Date:  2007-07-14       Impact factor: 5.858

3.  ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

Authors:  D L Donnelly-Roberts; P S Puttfarcken; T A Kuntzweiler; C A Briggs; D J Anderson; J E Campbell; M Piattoni-Kaplan; D G McKenna; J T Wasicak; M W Holladay; M Williams; S P Arneric
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

4.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.

Authors:  A W Bannon; M W Decker; M W Holladay; P Curzon; D Donnelly-Roberts; P S Puttfarcken; R S Bitner; A Diaz; A H Dickenson; R D Porsolt; M Williams; S P Arneric
Journal:  Science       Date:  1998-01-02       Impact factor: 47.728

6.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion.

Authors:  M Shoaib; J Gommans; A Morley; I P Stolerman; R Grailhe; J-P Changeux
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

7.  GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue.

Authors:  F van Haaren; K G Anderson; S C Haworth; W R Kem
Journal:  Pharmacol Biochem Behav       Date:  1999-10       Impact factor: 3.533

8.  In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile.

Authors:  John Malysz; Jens Halvard Grønlien; David J Anderson; Monika Håkerud; Kirsten Thorin-Hagene; Hilde Ween; Caroline Wetterstrand; Clark A Briggs; Ramin Faghih; William H Bunnelle; Murali Gopalakrishnan
Journal:  J Pharmacol Exp Ther       Date:  2009-04-23       Impact factor: 4.030

Review 9.  Multiple roles for nicotine in Parkinson's disease.

Authors:  Maryka Quik; Luping Z Huang; Neeraja Parameswaran; Tanuja Bordia; Carla Campos; Xiomara A Perez
Journal:  Biochem Pharmacol       Date:  2009-05-09       Impact factor: 5.858

Review 10.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

View more
  8 in total

Review 1.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

2.  Attenuation of nicotine taking and seeking in rats by the stoichiometry-selective alpha4beta2 nicotinic acetylcholine receptor positive allosteric modulator NS9283.

Authors:  John J Maurer; Karin Sandager-Nielsen; Heath D Schmidt
Journal:  Psychopharmacology (Berl)       Date:  2016-11-14       Impact factor: 4.530

3.  An Accessory Agonist Binding Site Promotes Activation of α4β2* Nicotinic Acetylcholine Receptors.

Authors:  Jingyi Wang; Alexander Kuryatov; Aarati Sriram; Zhuang Jin; Theodore M Kamenecka; Paul J Kenny; Jon Lindstrom
Journal:  J Biol Chem       Date:  2015-04-13       Impact factor: 5.157

4.  Potentiation of a neuronal nicotinic receptor via pseudo-agonist site.

Authors:  Simone Mazzaferro; Isabel Bermudez; Steven M Sine
Journal:  Cell Mol Life Sci       Date:  2019-01-01       Impact factor: 9.261

Review 5.  Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders.

Authors:  Alvin V Terry; Patrick M Callahan; Caterina M Hernandez
Journal:  Biochem Pharmacol       Date:  2015-07-29       Impact factor: 5.858

Review 6.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

7.  Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms.

Authors:  Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj
Journal:  Neuropharmacology       Date:  2021-04-18       Impact factor: 5.273

8.  Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers.

Authors:  R L Ashare; B A Kimmey; L E Rupprecht; M E Bowers; M R Hayes; H D Schmidt
Journal:  Transl Psychiatry       Date:  2016-01-19       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.